Treatment Bridging with a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study

(2020) Paul G Richardson et al.   Lancet Haematology

Bispecifics, trispecifics, and other novel immune treatments in myeloma

(2020) Guido Lancman et al.   Hematology-American Society of Hematology Education Program

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

The microenvironment in myeloma

(2019) Oliver C. Lomas et al.   CURRENT OPINION IN ONCOLOGY

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis

(2018) Marjorie Pick et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma

(2013) X. Papanikolaou et al.   HAEMATOLOGICA

The possible role of chemotherapy in antiangiogenic drug resistance

(2012) Guido Bocci et al.   MEDICAL HYPOTHESES